Formycon and Fresenius Kabi have concluded a resolution for their biosimilar contender FYB202, based on ustekinumab, targeting markets in Europe and Canada.

KeChow Pharma announces that its drug Tunlametinib (HL-085) has been approved by the NMPA, becoming the first targeted therapy approved for the treatment of NRAS-mutant advanced melanoma patients who have been previously treated with PD-1/PD-L1 therapy.

Shaperon has initiated enrollment of its inaugural participant in the second-stage American clinical study for its eczema treatment, branded as Nugel.

Promising phase III results for RUBY suggest expanded use of Jemperli (dostarlimab-gxly) paired with other treatments in cases of initial severe or returning uterine cancer.

AstraZeneca plans to purchase Amolyt Pharma, thereby broadening its advanced portfolio in uncommon disorders.

Lirum BioMed Reveals Encouraging Results for Its Innovative Treatment LX-101, Showing Strong Early-Phase Effectiveness in Tackling IGF-Linked Tumors, Scheduled for Discussion at the 2024 ESMO Congress on Sarcoma and Uncommon Cancers.

Nuvectis Pharma Releases Promising Initial Results from Early-Stage NXP800 Study in Platinum-Resilient Ovarian Cancer with ARID1a Alterations.

Mozart Therapeutics Showcases Preliminary Data for Key Project, MTX-101, Aimed at Autoimmune Condition Management, at the 2024 Society of Toxicology Gathering.

Madrigal Pharmaceuticals Reveals Rezdiffra™ (resmetirom) Gets Green Light from FDA to Manage Noncirrhotic NASH Sufferers with Moderate to Severe Fibrotic Liver Conditions.

Zai Lab Limited plans to present early data highlighting the potential therapeutic effects of its global antibody-drug conjugate project, ZL-1310.

FDA Grants Authorization for Mirum Pharmaceuticals' Drug LIVMARLI to Treat Itchy Skin Caused by Bile Buildup in Individuals with Advanced Hereditary Liver Disorder.

Almirall has entered into an exclusive licensing deal with Eloxx Pharmaceuticals for the use of ZKN-013 in the treatment of uncommon skin conditions.